NIH/NCI Renews and Expands Nation-Wide License for Genomatix Software and Databases
News Sep 28, 2007
Genomatix Software Inc., the newly incorporated subsidiary of Genomatix Software GmbH, has announced that it has renewed and extended its software licensing agreement with the NCI/NIH for the fourth consecutive year.
This year’s renewal marks a benchmark in the company’s history as the renewal was executed entirely between the US company and the NCI/NIH campus in Bethesda, MD.
“We are extremely pleased with our progress in putting the US company on its feet, and the renewal with NCI/NIH is a huge step in firmly establishing our presence here”, said Peter Grant, CEO of the US company.
“Our mission is to expand the presence of Genomatix and its capabilities for understanding gene regulation in North America, and NCI/NIH have clearly gotten the message. Their renewal has grown with us each year, and this year represents the biggest increase yet.”
Klaus May, Chief Business Officer of the Munich based company and Board Chairman of the US company commented: “Genomatix realized several years ago that to properly service the North American market, you needed a North American presence.
We have already seen significant gains in the short time since the US operation was established, and the increase in the NCI/NIH renewal accurately reflects the wisdom of that decision. We are very pleased with the rapid progress the US company has made in growing the business and expanding the awareness of our product.”
Genomatix is a pioneer and leader in the analysis and understanding of eukaryotic gene regulation. Core competences at Genomatix are annotation driven microarray analysis, ChIP on chip, regulatory network and pathway mining, and promoter analysis on sequence level.
Genomatix has published more than 170 peer reviewed scientific papers that have been cited in more than 4,000 papers. Over 35,000 researchers worldwide currently apply Genomatix tools and databases.
Nonalcoholic fatty liver disease produces no noticeable symptoms, but one out of every five people with it will go on to develop a more serious conditions such as nonalcoholic steatohepatosis and cirrhosis. Three new studies investigate how mitochondrial energy production is altered by the progress of fatty liver disease.READ MORE